FLI1: A Potential Drug Target and Biomarker for Leukemia (G2313)

Target Name: FLI1

NCBI ID: G2313

FLI1

FLI1: A Potential Drug Target and Biomarker for Leukemia

Leukemia is a type of cancer that affects the bone marrow and blood cells. It is a serious disease that can be treated with various chemotherapy drugs, but the high risk of side effects often leads to a poor prognosis. Researchers have been investigating new treatments and drug targets for leukemia, with a focus on identifying potential biomarkers and drug targets. In this article, we will discuss FLI1, a transcription factor that has been identified as a potential drug target and biomarker for leukemia.

FLI1: The Transcription Factor

FLI1 is a non-coding RNA molecule that is expressed in various tissues, including the brain, heart, and gastrointestinal tract. It is a member of the POU5F1 gene family, which is known for its role in the development and maintenance of tissues. FLI1 has been shown to play a role in the development and progression of various diseases, including leukemia.

FLI1 has been shown to promote the growth and proliferation of leukemia cells. In a study published in the journal PLoS One, researchers found that FLI1 was highly expressed in human leukemia samples and was associated with the development of leukemia. The study also showed that inhibiting FLI1 reduced the growth and proliferation of leukemia cells.

FLI1 as a Potential Drug Target

FLI1 is a potential drug target because of its role in the development and progression of leukemia. By targeting FLI1, researchers can potentially inhibit the growth and proliferation of leukemia cells and slow down or stop the progression of the disease. There are several different approaches that researchers have used to target FLI1, including inhibition of its activity with small molecules, antibodies, and RNA-based therapeutics.

In addition to its potential as a drug target, FLI1 has also been identified as a potential biomarker for leukemia. Leukemia can be difficult to diagnose, and the disease often goes undetected until it is advanced. By using FLI1 as a biomarker, researchers can potentially diagnose leukemia at an early stage, when it is more easily treatable.

FLI1 as a Potential Biomarker

FLI1 has been shown to be expressed in various types of leukemia, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). It has also been shown to be associated with the transition from a normal to a leukemia-like state. Therefore, FLI1 has the potential to be used as a biomarker for various types of leukemia.

FLI1 has been shown to be expressed in the blood and bone marrow of patients with AML, a type of leukemia that is characterized by the production of abnormal white blood cells. In addition, studies have shown that FLI1 is expressed in the bone marrow of patients with BPDCN, a type of leukemia that is characterized by the production of blastic cells that are part of the immune system.

FLI1 has also been shown to be expressed in the blood and bone marrow of patients with MDS, a type of leukemia that is characterized by the production of abnormal white blood cells and the development of blood cancers. In addition, studies have shown that FLI1 is expressed in the bone marrow of patients with various types of non-leukemia malignancies, including breast cancer and colon cancer.

FLI1 as a Potential Drug Target

FLI1 is a potential drug target because of its role in the development and progression of leukemia. By targeting FLI1, researchers can potentially inhibit the growth and proliferation of leukemia cells and slow down or stop the progression of the disease. There are several different approaches that researchers have used to

Protein Name: Fli-1 Proto-oncogene, ETS Transcription Factor

Functions: Sequence-specific transcriptional activator (PubMed:24100448, PubMed:26316623, PubMed:28255014). Recognizes the DNA sequence 5'-C[CA]GGAAGT-3'

The "FLI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets